Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(100%)

Phase Distribution

Phase 2/3
1
50%
Not Applicable
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2/3Combined phases
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2/3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(2)

Detailed Status

Terminated2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 2/3

Trials by Phase

Phase 2/31 (50.0%)
N/A1 (50.0%)

Trials by Status

terminated2100%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_2_3

Furosemide as Supportive Therapy for COVID-19 Respiratory Failure

NCT04588792
terminatednot_applicable

Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease

NCT00180843

Clinical Trials (2)

Showing 2 of 2 trials
NCT04588792Phase 2/3

Furosemide as Supportive Therapy for COVID-19 Respiratory Failure

Terminated
NCT00180843Not Applicable

Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease

Terminated

All 2 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
2